BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28592047)

  • 21. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

  • 22. The future of NSCLC: molecular profiles guiding treatment decisions.
    Tsao AS; Papadimitrakopoulou VA
    Oncology (Williston Park); 2011 Jun; 25(7):607, 614. PubMed ID: 21888260
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.
    Yin JY; Li X; Zhou HH; Liu ZQ
    Pharmacogenomics; 2016 Aug; 17(12):1365-78. PubMed ID: 27462924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
    Codacci-Pisanelli G; Frati L; Mini E
    J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
    [No Abstract]   [Full Text] [Related]  

  • 25. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The molecular markers related to personalized therapy of non-small cell lung cancer].
    Guo N; Yu C; Yu C
    Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):292-6. PubMed ID: 21426677
    [No Abstract]   [Full Text] [Related]  

  • 27. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 28. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy in nonsmall cell lung cancer.
    Puri T
    Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 31. [Personalized therapy of lung cancer - current standard and future challenges].
    Riedel R; Wolf J
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Potential Epigenetic Therapy for NSCLC.
    Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted lung cancer therapies.
    Farmer G
    Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
    [No Abstract]   [Full Text] [Related]  

  • 34. Current status of targeted therapy in non-small cell lung cancer.
    Parums DV
    Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy of non-small-cell lung carcinoma.
    Tiwari D; Brodie SA; Brandes JC
    Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity.
    Swanton C; Burrell RA
    Cancer Biol Ther; 2009 Nov; 8(21):2051-3. PubMed ID: 19816149
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular targeted therapies and cytotoxics: Friends or foes?].
    Vignot S; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
    [No Abstract]   [Full Text] [Related]  

  • 40. [Application strategies of the third-generation EGFR-TKI in the context of precision medicine].
    Zhao J; Zhang SJ; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):86-89. PubMed ID: 28219200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.